Short interest for United Therapeutics gives investors a sense of the degree to which investors are betting on the decline of United Therapeutics's stock. Short interest data is updated every two weeks.

United Therapeutics Stock (NASDAQ:UTHR), Short Interest Report

United Therapeutics

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

UTHR

Biotech

Earnings

Large Cap

News

Guidance

Health Care

Movers

General

United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyvaso leads the charge with a 56% revenue surge.

Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity

Image 4

Intraday Update

Markets

AMCR

ATEN

AXTA

CDNA

CHEF

DOCN

GRMN

LIVN

LMND

NARI

NYCB

PINS

POWL

RCKY

ROOT

SRDX

STGW

TECH

TGTX

TMDX

UFPT

Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday

Legal

LQDA

Legal battle unfolds as United Therapeutics challenges FDA&#39;s handling of Liquidia&#39;s drug approval process. Explore the implications on PH-ILD, potential 30-month stay, and recent financial performance.

United Therapeutics&#39; Challenges FDA Over Liquidia&#39;s Drug Approval Process, Clocks Strong Q4 Earnings

United Therapeutics Corporation - Common Stock

United Therapeutics Corp

Goldman Sachs analyst Chris Shibutani maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Neutral and raises the price target from $218 to $240.

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on United Therapeutics, Raises Price Target to $240

Throughout the last three months, 7 analysts have evaluated United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated United Therapeutics and provided 12-month price targets. The average target is $311.14, accompanied by a high estimate of $400.00 and a low estimate of $215.00. Surpassing the previous average price target of $299.00, the current average has increased by 4.06%.
<img src="https://www.benzinga.com/files/images/story/2024/1714654837_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive United Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$309.00</td>
</tr>
<tr>
<td>Liana Moussatos</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$308.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Roanna Ruiz</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$330.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of United Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of United Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind United Therapeutics</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>United Therapeutics: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 25.07%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 35.32%, the company may face hurdles in effective cost management.
Return on Equity (ROE): United Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.71%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): United Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 3.06%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For United Therapeutics

Oppenheimer analyst Hartaj Singh maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Outperform and raises the price target from $375 to $400.

Oppenheimer Maintains Outperform on United Therapeutics, Raises Price Target to $400

HC Wainwright &amp; Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and maintains $300 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price Target

On Wednesday,&nbsp;United Therapeutics Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) reported first-quarter sales of $677.7 million, up 34%&nbsp;year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $623.9 million</a>.
The company reported EPS of $6.17, up from $4.86 a year ago, surpassing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38544435/united-therapeutics-corporation-reports-first-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $5.56</a>.
&#8220;The first quarter of 2024 represents another quarter of record revenue and double-digit year-over-year revenue growth,&#8221;&nbsp;jointly&nbsp;said&nbsp;Martine Rothblatt, Chairperson and Chief Executive Officer&nbsp;and&nbsp;Michael Benkowitz, President and Chief Operating Officer.&nbsp;
&#8220;That growth, coupled with our upcoming clinical reads, puts us in a unique position in the biotech industry: a company with a solid and growing commercial foundation, near-term clinical catalysts, and the potential to provide an unlimited supply of tolerable, transplantable organs.&#8221;
&#8220;Our distinctive commercial and clinical profile, alongside our solid balance sheet and cash flow potential, makes United Therapeutics a compelling investment opportunity,&#8221; said&nbsp;James Edgemond, Chief Financial Officer and Treasurer. &#8220;That&#8217;s why we implemented a $1 billion accelerated share repurchase that concretely demonstrates our belief in our near-term and long-term potential despite potential competition emerging this year.&#8221;
Tyvaso revenues grew by 56% to&nbsp;$372.5 million, primarily due to an increase in quantities sold and continued growth in commercial utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to some extent, due to price increases.
Tyvaso DPI revenues increased 92% to&nbsp;$227.5 million. Nebulized Tyvaso sales reached $145 million, up 21%.
Orenitram sales increased 20% to $106.2 million&nbsp;and Unituxin&nbsp;sales reached $58.4 million,&nbsp;up 19%.
The company&nbsp;<a target="_blank" href="https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/events-and-presentations/q1-2024-investor-presentation.pdf" rel="noreferrer noopener">highlighted</a>&nbsp;that it&nbsp;reported the highest quarterly revenue for Tyvaso, Orenitram, and Unituxin.
Price Action: UTHR shares are up 8% at $253.08&nbsp;at&nbsp;the last check Wednesday.

U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday.
Shares of Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) rose sharply during Wednesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/POWL/earnings">second-quarter financial results</a>.
Powell Industries posted GAAP earnings of $2.75 per share, beating market estimates of $1.77 per share. The company's quarterly sales came in at $255.108 million versus expectations of $201.447 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Powell Industries shares jumped 23.2% to $176.16 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Rocky Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) shares jumped 31.6% to $33.93 after the company reported better-than-expected quarterly financial results.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares climbed 28% to $120.26 after the company raised its 2024 guidance.</li>
<li>Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) rose 27.2% to $32.69 following strong quarterly results.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) shares gained 23.4% to $9.59. CareDx is expected to report financial results for the first quarter 2024 after the closing bell on Thursday, May 9.</li>
<li>TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) rose 21.7% to $16.64 following a first-quarter revenue beat and increased 2024 Briumvi US net product revenue outlook.</li>
<li>New York Community Bancorp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) jumped 20% to $3.1887 following quarterly results.</li>
<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) rose 20.1% to $75.89 following upbeat quarterly results.</li>
<li>Inari Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) shares gained 19.1% to $44.47 after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) surged 18% to $8.87.</li>
<li>A10 Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) climbed 17.7% to $15.38 following better-than-expected quarterly results.</li>
<li>Pinterest, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) gained 17.5% to $39.29 following strong first-quarter earnings and upbeat second-quarter guidance.</li>
<li>Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) shares gained 17.2% to $81.66 after the company reported better-than-expected first-quarter financial results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) rose 17.2% to $8.82 following upbeat earnings.</li>
<li>UFP Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) gained 13.8% to $234.34 following upbeat earnings.</li>
<li>Stagwell Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) rose 13.1% to $6.73 following upbeat earnings.</li>
<li>The Chefs&#8217; Warehouse, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) gained 11.5% to $36.89 following strong quarterly earnings.</li>
<li>Garmin Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NASDAQ">GRMN</a>) climbed 11% to $160.40 after the company reported better-than-expected first-quarter financial results and affirmed FY24 adjusted EPS and sales guidance, which is above estimates.</li>
<li>Amcor plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>) gained 10% to $9.84 after the company reported mixed third-quarter financial results and updated guidance.</li>
<li>Trinity Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRN#NYSE">TRN</a>) rose 9.4% to $28.48 following upbeat earnings.</li>
<li>Axos Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) surged 9.3% to $55.31 following better-than-expected earnings.</li>
<li>Axalta Coating Systems Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) gained 9.2% to $34.32 following better-than-expected quarterly results.</li>
<li>Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) climbed 8.1% to $92.61 on strong quarterly earnings.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) rose 8.1% to $78.39 as the company reported a first-quarter fiscal 2024 sales decline of 3% year-over-year to $2.931 billion, beating the consensus of $2.813 billion.</li>
<li>Clean Harbors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLH#NYSE">CLH</a>) gained 8% to $204.59 after the company reported better-than-expected quarterly financial results.</li>
<li>DigitalOcean Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) gained 7.7% to $35.38 after it was announced the stock will join the S&amp;P SmallCap 600.</li>
<li>LivaNova PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>) gained 7.4% to $59.86 after the company posted upbeat quarterly earnings and raised FY24 forecast.</li>
<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) gained 6.2% to $248.95 after the company reported better-than-expected quarterly financial results.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) shares rose 6% to $18.26 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38549444/exxon-mobil-kimberly-clark-and-2-other-stocks-insiders-are-selling">Exxon Mobil, Kimberly-Clark And 2 Other Stocks Insiders Are Selling</a>

WIIM

United Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) reported quarterly earnings of $6.17 per share which beat the analyst consensus estimate of $5.56 by 10.97 percent. This is a 26.95 percent increase over earnings of $4.86 per share from the same period last year. The company reported quarterly sales of $677.700 million which beat the analyst consensus estimate of $623.966 million by 8.61 percent. This is a 33.70 percent increase over sales of $506.900 million the same period last year.

Earnings Beats

United Therapeutics Q1 2024 GAAP EPS $6.17 Beats $5.56 Estimate, Sales $677.700M Beat $623.966M Estimate

The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant
This transplant builds on two successful UHeart transplants completed in 2022 and 2023

United Therapeutics Announces Xenothymokidney Transplant

Liquidia Says Judge Andrews Has Set Aside Injunction Issued In August 2022 In Lawsuit Filed By United Therapeutics, Hence FDA Is No Longer Enjoined From Issuing Final Approval Of Liquidia New Drug Application For Yutrepia (Treprostinil) Inhalation Powder

<h3>Gainers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 5.52% to $2.65. The company's market cap stands at $43.0 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock decreased by 22.9% to $0.29 during Tuesday's after-market session. The company's market cap stands at $23.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock fell 11.34% to $1.02. The company's market cap stands at $15.0 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 9.84% to $1.1. The market value of their outstanding shares is at $40.2 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares decreased by 7.21% to $3.6. The market value of their outstanding shares is at $4.2 million. </li>
<li>United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) shares declined by 7.21% to $230.0. The company's market cap stands at $10.8 billion. </li>
<li>ProSomnus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSA#NASDAQ">OSA</a>) stock decreased by 6.46% to $0.58. The market value of their outstanding shares is at $10.0 million. As per the press release, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

APLM

BSGM

CARA

COEP

ESLA

IRIX

MIRA

TTNP

VRPX

12 Health Care Stocks Moving In Tuesday's After-Market Session

United Therapeutics shares are trading higher after the company announced a $1 billion accelerated share repurchase program.

United Therapeutics Corporation (Nasdaq:&nbsp;UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to&nbsp;$1 billion&nbsp;of United Therapeutics&#39; common stock. This program builds on United Therapeutics&#39; planned&nbsp;$400 million&nbsp;paydown of its revolving credit facility in 2024, of which&nbsp;$100 million&nbsp;was paid down during the&nbsp;first quarter&nbsp;of 2024.

Buybacks

United Therapeutics Announces $1B Accelerated Share Repurchase Program

Liquidia&rsquo;s investigational product is currently tentatively approved by the FDA for the treatment of pulmonary arterial hypertension (PAH) but not PH-ILD. In this litigation, the Company alleges that Liquidia&rsquo;s product for use in pulmonary hypertension associated with interstitial lung disease (PH-ILD) infringes the Company&rsquo;s U.S. Patent No. 11,826,327 (the &rsquo;327 patent), which expires in 2042. The &rsquo;327 patent generally covers improving exercise capacity in patients suffering from PH-ILD by administering treprostinil by inhalation. In its preliminary injunction motion, the Company asked the district court to enjoin Liquidia from marketing its product for PH-ILD until the court can adjudicate the Company&rsquo;s infringement claims.
&nbsp;

United Therapeutics Filed Motion In U.S. District Court For The District Of Delaware For Preliminary Injunction In Its Patent Litigation With Liquidia Technologies' Efforts To Seek FDA Approval For PH-ILD For Its Inhaled Treprostinil Product-8K

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated United Therapeutics and provided 12-month price targets. The average target is $288.25, accompanied by a high estimate of $330.00 and a low estimate of $215.00. Marking an increase of 35.33%, the current average surpasses the previous average price target of $213.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1708610436_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of United Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liana Moussatos</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$308.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Roanna Ruiz</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$330.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of United Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>About United Therapeutics</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>Financial Insights: United Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 18.1%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 43.91%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): United Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.81%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): United Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 3.91%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock

Wedbush analyst Liana Moussatos reiterates United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Outperform and maintains $308 price target.

Wedbush Reiterates Outperform on United Therapeutics, Maintains $308 Price Target

Wednesday,&nbsp;United Therapeutics Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) initiated legal action against the FDA, claiming that the FDA wrongly allowed&nbsp;Liquidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) to deviate from established&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b37231366/united-therapeutics-commences-litigation-to-ensure-fairness-in-the-drug-review-process" rel="noreferrer noopener">rules in the drug approval process</a>.&nbsp;
The litigation focuses on the FDA&#8217;s handling of Liquidia&#8217;s amendment to a pending new drug application (NDA) related to its proposed inhaled dry powder treprostinil product, seeking to add a second indication for pulmonary hypertension associated with interstitial lung disease (PH-ILD).&nbsp;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37069483/this-united-therapeutics-analyst-is-no-longer-bearish-expects-mid-decade-4b-revenue" rel="noreferrer noopener">This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate</a>.
United Therapeutics contends that FDA rules require a new NDA for such a second indication rather than an amendment to an existing one.
The company also asserts that, under the Hatch-Waxman Act, Liquidia&#8217;s decision to file an amendment instead of a new NDA allowed it to avoid a potential 30-month stay on approval for PH-ILD.&nbsp;
This stay would be triggered if a timely patent infringement action is filed, preventing FDA approval until the litigation is resolved.&nbsp;
United Therapeutics had previously sued Liquidia for alleged infringement of a patent related to the PH-ILD indication.&nbsp;
The ongoing patent infringement case contends that Liquidia&#8217;s actions in seeking approval for PH-ILD infringe on United Therapeutics&#8217; patent rights.&nbsp;
The lawsuit is pending in the U.S. District Court for the District of Delaware.&nbsp;
If successful in its legal action against the FDA, United Therapeutics aims to secure a stay of up to 30 months on Liquidia&#8217;s final approval for PH-ILD, allowing for the resolution of the patent infringement litigation.
United Therapeutics reported a fourth-quarter 2023 EPS of $4.36, up from $2.67 a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $4.19</a>.
The company&#8217;s sales increased 25% to $614.70 million, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b37231427/united-therapeutics-corporation-reports-fourth-quarter-and-full-year-2023-financial-results" rel="noreferrer noopener">consensus of $575.87 million</a>.
Total Tyvaso revenues grew by 45% to $350.6 million in the fourth quarter of 2023, compared to $242.3 million a year ago, primarily due to an increase in quantities sold, driven by the commercial launch of Tyvaso DPI in June 2022 and continued growth in utilization by PH-ILD patients.
Price Action:&nbsp;UTHR shares are up 0.87% at $216.03 on the last check Wednesday.

United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) reported quarterly earnings of $4.36 per share which beat the analyst consensus estimate of $4.19 by 4.06 percent. This is a 63.3 percent increase over earnings of $2.67 per share from the same period last year. The company reported quarterly sales of $614.70 million which beat the analyst consensus estimate of $575.87 million by 6.74 percent. This is a 25.07 percent increase over sales of $491.50 million the same period last year.

United Therapeutics Q4 GAAP EPS $4.36 Beats $4.19 Estimate, Sales $614.70M Beat $575.87M Estimate

United Therapeutics Has Commenced Litigation Related To The FDA Inappropriately Denying United Therapeutics' Right To Obtain Stay Of Liquidia's Final Approval Until United Therapeutics' Pending Patent Infringement Claim Against Liquidia Can Be Resolved

United Therapeutics Q1 2024 Earnings Preview

United Therapeutics GAAP EPS of $6.17 beats by $0.51, revenue of $677.7M beats by $53.51M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
United Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/uthr-stock-quote/">UTHR</a>) just reported results for the first quarter of 2024.<ul><li>United Therapeutics reported earnings per share of $6.17. This was above the analyst estimate for EPS of $5.65.</li><li>The company reported revenue of $677.70 million.</li><li>This was 8.61% better than the analyst estimate for revenue of $623.97 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/uthr-stock-earnings-united-therapeutics-for-q1-of-2024/">UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024

United Therapeutics Corporation (UTHR) Q1 2024 Earnings Call Transcript

Analysts have been eager to weigh in on the Healthcare sector with new ratings on United Therapeutics (UTHR – Research Report), Moderna (MRNA – Res...

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Moderna (MRNA) and Neurocrine (NBIX)

Analyst Tiago Fauth of Wells Fargo maintained a Buy rating on United Therapeutics (UTHR – Research Report), retaining the price target of $325.00. ...

Buy Rating for United Therapeutics: Strong Performance and Growth Potential Despite Competitive Pressures

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on United Therapeutics (UTHR – Research Report), with a price ...

Buy Rating on United Therapeutics: Strong Market Position and Growth Potential Despite New Competitors

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on United Therapeutics (UTHR – Research Report), with a price tar...

United Therapeutics (UTHR) Gets a Buy from Oppenheimer

Analysts have been eager to weigh in on the Healthcare sector with new ratings on United Therapeutics (UTHR – Research Report) and BioRestorative T...

Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and BioRestorative Therapies (BRTX)

The biotechnology industry is thriving, fueled by solid government support, rising healthcare spending worldwide, gene editing breakthroughs, and rapid AI adoption. Hence, fundamentally solid biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and SIGA Technologies (SIGA) could be ideal buys for potential gains. Keep reading… The biotech industry is poised for robust growth thanks to the increasing number of innovative clinical solutions, growing demand for personalized medicines, advances in gene editing and cell therapy, and government initiatives. Further, technological advancements like AI open new avenues for industry players.
Given the industry's bright growth prospects, it could be wise to invest in quality biotech stocks Shionogi &amp; Co., Ltd. (<a href="https://stocknews.com/stock/SGIOY/">SGIOY</a>), United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>), and SIGA Technologies Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>) for substantial returns.
As part of President Biden's investment in America agenda, the White House recently launched the <a href="https://www.whitehouse.gov/ostp/news-updates/2024/03/22/the-white-house-advances-biotechnology-and-biomanufacturing-leadership-with-the-launch-of-the-national-bioeconomy-board/">National Bioeconomy Board</a> as an essential step toward realizing the potential of biotechnology for the economy and advancing Biotechnology and Biomanufacturing leadership.
The stated Board will function with partners from the public and private sectors to advance societal well-being, national security, sustainability, economic productivity, and competitiveness with biotechnology and biomanufacturing.
With more patients requiring better treatment, especially in immunology, endocrinology, and oncology, the global medicine market's spending is rapidly expanding, of which the <a href="https://www.iqvia.com/newsroom/2024/01/global-medicine-spending#:~:text=Spending%20and%20growth%20by%20regions,trillion%20in%20total%20market%20size.">global spending on biotech</a> is expected to represent 39%, exceeding $892 billion by 2028 and will include breakthrough cell and gene therapies and maturing biosimilar segment.
The global biotechnology market revenue is expected to total $3.88 trillion by 2030, growing at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a> during the forecast period (2024-2030). Further, the <a href="https://www.biospace.com/article/releases/u-s-biotechnology-market-size-to-hit-usd-1-785-96-billion-by-2033/">U.S. biotechnology market</a> is anticipated to hit around $1.78 trillion by 2033, expanding at a CAGR of 12.5%.
Further, the rapid adoption of cutting-edge technologies such as artificial intelligence (AI) and machine learning are expediting the identification, development, and healthcare applications of drugs, revolutionizing the biotech segment. The <a href="https://www.precedenceresearch.com/artificial-intelligence-in-biopharmaceutical-market">global AI in the biopharmaceutical market</a> is estimated to reach around $14.07 billion by 2032, growing a CAGR of 32.3%.
Moreover, investors' interest in biotech stocks is evident from iShares Nasdaq Biotechnology Index Fund ETF's (<a href="https://stocknews.com/stock/IBB/">IBB</a>) 9.3% returns over the past six months.
Given the industry's favorable prospects, let's delve into the fundamentals of the three best <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, beginning with the third choice.
Stock #3: Shionogi &amp; Co., Ltd. (<a href="https://stocknews.com/stock/SGIOY/">SGIOY</a>)
Headquartered in Osaka, Japan, SGIOY engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its product portfolio includes Fetroja, Cabenuva and Apretude, Xocova, Finibax, Xofluza, and Tivicay.
On April 15, SGIOY's subsidiary, Taiwan Shionogi &amp; Co., Ltd., received approval for a supplemental New Drug Application for Xofluza&#xAE; for the treatment and postexposure prophylaxis for influenza virus infection for pediatrics aged 5 to less than 12 years. The newly approved indication extends treatment options and offers a new choice for managing influenza.
On April 11, SGIOY's European subsidiary, Shionogi B.V., announced that the European Commission had granted Orphan Medicinal Product designation for zatolmilast, an investigational treatment for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism. This designation is a significant milestone for the company.
SGIOY is dedicated to bringing new and innovative medicines to the market for rare pediatric and orphan diseases, and this regulatory designation in Europe is a recognition of the potential clinical benefit of zatolmilast.
SGIOY reported a revenue of ¥336.82 billion ($2.18 billion) for the nine months ended December 31, 2023. Its <a href="https://www.investopedia.com/terms/o/operating_profit.asp">operating profit</a> was ¥138.74 billion ($896.94 million) over the same period. The company's profit attributable to owners of parent and EPS came in at ¥27.22 billion ($822.48 million) and ¥435.74, respectively.
Furthermore, the company's comprehensive income increased 10.6% year-over-year to ¥ 183.44 billion ($1.18 billion). Its total assets stood at ¥1.36 trillion ($8.79 billion) as of December 31, 2023, compared to ¥1.31 trillion ($8.47 billion) as of March 31, 2023.
Street expects SGIOY's revenue for the fourth quarter (ended March 2024) to increase 8% year-over-year to $710.11 million. For the fiscal year 2024, the company's revenue is expected to grow 4.6% year-over-year to $2.88 billion. Moreover, SGIOY has topped the consensus revenue estimates in each of the trailing four quarters.
Over the past year, SGIOY's stock has climbed 6.7% to close the last trading session at $11.87.
SGIOY's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
SGIOY has a B grade for Value and Quality. It is ranked #17 out of 358 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
In addition to the POWR Ratings we've stated above, we also have SGIOY's other ratings for Momentum, Sentiment, Growth, and Stability. Get all SGIOY ratings <a href="https://stocknews.com/stock/SGIOY/">here</a>.
Stock #2: United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>)
UTHR is a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally. The company provides Tyvaso DPI, Tyvaso, Remodulin (treprostinil) injection, Orenitram, and Adcirca.
On April 24, 2024, UTHR announced the world's first successful transplant of a UThymoKidney&#x2122;, which the company produced, into a living person on April 12, 2024. This transplant represented several historic firsts for transplantation, including the first-ever transplant of a xenothymokidney into a living human recipient.
It also marked the first-ever combined mechanical heart pump and organ transplant and the first-ever xenotransplant into a living human using only FDA-approved immunosuppressive medicines.
On December 13, 2023, UTHR's wholly-owned subsidiary, Morpheus Subsidiary Inc., acquired all outstanding shares of Miromatrix Medical Inc. (<a href="https://stocknews.com/stock/MIRO/">MIRO</a>) for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash. The acquisition is expected to expand UTHR's existing complementary platform of organ manufacturing programs.
During the first quarter that ended March 31, 2024, UTHR's total revenues increased 33.7% year-over-year to $677.70 million. Its operating income grew 25.3% from the year-ago value to $356.30 million. The company's net income came in at $306.60 million, or $6.17 per common share, up 27.3% and 26.9% from the previous year's quarter, respectively.
As of December 31, 2023, the company's cash, cash equivalents and marketable investments, and total assets totaled $4.20 billion and $6.49 billion, respectively.
Analysts expect UTHR's revenue for the second quarter (ending June 2024) to increase 14.7% year-over-year to $684.32 million. The consensus EPS estimate for the ongoing quarter of $6.19 indicates 18.2% year-over-year growth. Furthermore, the company surpassed the consensus revenue and EPS estimates in all four trailing quarters.
UTHR's stock has surged 13% over the past month and 13.1% over the past six months to close the last trading session at $258.13.
UTHR's POWR Ratings reflect its bright prospects. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Value and a B for Growth and Quality. UTHR is ranked #12 among 358 stocks in the Biotech industry.
To access UTHR's additional ratings (Sentiment, Stability, and Momentum), <a href="https://stocknews.com/stock/UTHR/">click here</a>.
Stock #1: SIGA Technologies Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>)
SIGA is a commercial-stage pharmaceutical company focused on health security-related markets. The company's lead product includes TPOXX, an oral formulation antiviral drug for treating human smallpox disease caused by the variola virus.
On April 1, SIGA announced an amendment to its international promotion agreement with Meridian Medical Technologies, Inc., under which SIGA will drive international promotion activities for oral TPOXX&#xAE; while maintaining its contractual relationship with Meridian to maintain continuity for crucial customer relationships.
The company believes the amendment in the Meridian promotion agreement will be instrumental in driving long-term growth opportunities for oral TPOXX.
On March 12, SIGA's Board of Directors declared a special cash dividend of $0.60 per share on its common stock, representing an increase of $0.15 per share, or 33%, over the June 2023 special dividend. This reflects the company's robust capital structure and its ability to provide stable growth in the long run.
The dividend was paid on April 11, 2024, to shareholders of record at the close of business on March 26, 2024.
For the fiscal year that ended December 31, 2023, SIGA's total revenues rose 26.3% year-over-year to $139.92 million, and its operating income grew 95.8% from the prior period to $83.62 million. The company's net income and EPS of $68.07 million and $0.95 indicate growth of 100.8% and 106.5% year-over-year, respectively.
Also, as of December 31, 2023, the company's cash and cash equivalents were $150.14 million, compared to $98.79 million as of December 31, 2022.
Analysts expect SIGA's revenue and EPS for the fiscal year (ending December 2024) to increase 36.2% and 24.2% year-over-year to $190.60 million and $1.18, respectively.
Shares of SIGA have gained 93.1% over the past six months and 84.8% over the past year to close the last trading session at $9.44.
SIGA's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
The stock has an A grade for Value, Growth, and Quality. Within the same industry, SIGA is ranked #6 of 358 stocks.
<a href="https://stocknews.com/stock/SIGA/">Click here</a> to access additional ratings of SIGA for Momentum, Sentiment, and Stability.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
SGIOY shares were unchanged in premarket trading Friday. Year-to-date, SGIOY has declined -0.85%, versus a 7.75% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/sgioy-uthr-siga-miro-3-biotech-stocks-to-consider-buying-right-away/>3 Biotech Stocks to Consider Buying Right Away</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks to Consider Buying Right Away

BRTX

MIRO

MRNA

NBIX

SGIOY

SIGA

Press Releases

United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results

United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference

-

-

-

-

-

-

-

-

-

-

-

-

-

-

United Therapeutics Stock (NASDAQ:UTHR), Short Interest Report

People Also Watch